vimarsana.com

Page 43 - நோய்த்தடுப்பு நடவடிக்கை கூட்டணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson one-dose COVID-19 shot offers strong protection, fuels concern about variants

Johnson & Johnson one-dose COVID-19 shot offers strong protection, fuels concern about variants A single-dose vaccine is a big advantage when most countries are struggling to get shots in arms more quickly. A participant in a Johnson & Johnson vaccine trial at the Desmond Tutu HIV Foundation Youth Center near Cape Town, South Africa, Dec. 5, 2020. Johnson & Johnson s vaccine’s efficacy rate dropped from 72 percent in the United States to 57 percent in South Africa, where a highly contagious variant is driving most cases. [Carl Zimmer, Noah Weiland, Sharon LaFraniere/Joao Silva] © 2020 The New York Times Johnson & Johnson, the only major drugmaker developing a single-dose vaccine for COVID, announced Friday that its shot provided strong protection against COVID-19

The Better Business Bureau is warning people not to post their Covid-19 vaccination cards on social media

The Better Business Bureau is warning people not to post their Covid-19 vaccination cards on social media No matter how excited you are about getting your vaccine, the Better Business Bureau is warning you: Avoid sharing photos of your Covid-19 vaccine cards.. Posted: Feb 1, 2021 7:07 AM Posted By: CNN No matter how excited you are about getting your vaccine, the Better Business Bureau is warning you: Avoid sharing photos of your Covid-19 vaccine cards. Unfortunately, your card has your full name and birthday on it, as well as information about where you got your vaccine, said the BBB in a news release. If your social media privacy settings aren t set high, you may be giving valuable information away for anyone to use.

What s the Use of a Pretty Good Vaccine?

Johnson & Johnson: Why Less-Effective Vaccines Are Valuable

Michael Ciaglo / Getty Last spring and summer, when a COVID-19 vaccine was only a glimmer of hope on the horizon, scientists warned in their careful way that vaccines might not live up to the public’s high expectations. The FDA said a vaccine needed to be just 50 percent effective. The most important thing, scientists told me, was that the vaccines at least protect against severe illness. Then, in the fall, data from the Pfizer and Moderna vaccine trials demonstrated 95 percent and 94 percent efficacy, respectively, against all symptomatic infections. They smashed expectations and created new ones. In comparison, the results from other vaccine trials look pretty good but unspectacular: AstraZeneca’s vaccine looks to be 70 percent effective; Novavax’s achieved 89 percent efficacy in the U.K., but only 49 percent in South Africa, based on data released yesterday; and Johnson & Johnson’s demonstrated 66 percent efficacy against moderate and severe infection, based on results r

Mass vaccination clinics to play key role in ending COVID pandemic

5:28 pm UTC Jan. 28, 2021 SAN FRANCISCO – Jim Stephens got the text at 8 p.m. and was so excited he couldn t sleep. He had an appointment the next morning to get a COVID-19 vaccine at the city s first mass vaccination clinic.  The 76-year-old drove up after it opened at 8 a.m. and was waved into a line of cars flowing slowly but steadily through a temporary chain-link fence. He drove along a line of volunteers, making choreographed stops. First, his appointment paperwork was checked. At the next checkpoint, he was given a surgical mask. A few feet farther, a volunteer went over possible side effects.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.